{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:24:33Z","timestamp":1777983873442,"version":"3.51.4"},"reference-count":48,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Strat\u00e9giai K + F m\u0171helyek kiv\u00e1l\u00f3s\u00e1ga: A peptiderg szignaliz\u00e1ci\u00f3 komplexit\u00e1sa \u00e9s szerepe sziszt\u00e9m\u00e1s betegs\u00e9gekben","award":["PEPSYS GINOP-2.3.2\u201315-2016\u201300050"],"award-info":[{"award-number":["PEPSYS GINOP-2.3.2\u201315-2016\u201300050"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["TKP-2021-EGA-10"],"award-info":[{"award-number":["TKP-2021-EGA-10"]}]},{"name":"EUSTAR Database Improvement Grant - 2024"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Scleroderma and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To investigate the impact of gastrointestinal involvement in systemic sclerosis affecting the quality of life and systemic sclerosis-related disability using patient-reported outcome measurements (PROMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from 160 consecutive systemic sclerosis patients were collected, including clinical characteristics and self-assessment questionnaires. The severity of gastrointestinal involvement was determined by the University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA-GIT 2.0): patients were classified as having \u201cnone-to-mild\u201d symptoms (total score = 0.00\u20130.49: Group A), \u201cmoderate\u201d symptoms (Group B), and \u201csevere-to-very severe\u201d symptoms (Group C). All investigations were repeated following 1\u2009year to check the reliability (n\u2009=\u2009149).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Quality of life (EuroQol-5 Dimension anxiety\/depression, Physical Component Summary, and Mental Component Summary of Short-Form Health Survey-36) and disability questionnaires (Health Assessment Questionnaire Disability Index, Scleroderma Health Assessment Questionnaire), Scleroderma Impact of Disease showed moderate significant correlation with UCLA-GIT 2.0 (rho: 0.400, \u22120.484, \u22120.468, 0.400, 0.436, 0.646, respectively). These correlations remained significant when tested in the two main subgroups (limited and diffuse cutaneous systemic sclerosis). Disease duration and UCLA-GIT 2.0 score did not show any correlation (rho: .055, p\u2009=\u20090.488). The average gastrointestinal involvement complaint of early systemic sclerosis (disease duration\u2009&lt;\u20093\u2009years, n\u2009=\u200924) subgroup measured by the UCLA-GIT 2.0 was not different from the rest of the cases (0.13 (0.03-0.46) vs 0.22 (0.08-0.45), p\u2009=\u20090.280). All investigated PROMs regarding quality of life and disability showed worse results in Group B when compared with patients in Group A. Similarly, patients in Group C have worse results compared to Group B. These correlations with the UCLA-GIT 2.0 score were confirmed during the 1-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Moderate\/severe gastrointestinal involvement symptoms based on the UCLA-GIT 2.0 are associated with worse quality of life and disability. This correlation holds for both systemic sclerosis subgroups and independent of disease duration: moderate\/severe gastrointestinal involvement complaints develop early in systemic sclerosis parallel with early onset of decreased quality of life and disability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23971983251345284","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:13:40Z","timestamp":1749093220000},"page":"597-605","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported gastrointestinal involvement is associated with reduced quality of life and disability in systemic sclerosis"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-6834","authenticated-orcid":false,"given":"Patrik","family":"K\u00e9ringer","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin T","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7392-4114","authenticated-orcid":false,"given":"Gabriella","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"\u00c1goston-Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krist\u00f3f","family":"Filip\u00e1nits","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciska Ilona","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2159-6776","authenticated-orcid":false,"given":"Attila","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-2918","authenticated-orcid":false,"given":"G\u00e1bor","family":"Kum\u00e1novics","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"4","key":"e_1_3_3_2_2","first-page":"61","article-title":"The presence of small joint contractures is a risk factor for survival in 439 patients with systemic sclerosis","volume":"35","author":"Nagy G","year":"2017","unstructured":"Nagy G, Minier T, Varj\u00fa C, et al. The presence of small joint contractures is a risk factor for survival in 439 patients with systemic sclerosis. Clin Exp Rheumatol 2017; 35 (suppl 106)(4): 61\u201370.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319891282"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq147"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397198321992197"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-0970-z"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203889"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex182"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq310"},{"issue":"8","key":"e_1_3_3_10_2","first-page":"1718","article-title":"Disease and symptom burden in systemic sclerosis: a patient perspective","volume":"34","author":"Suarez-Almazor ME","year":"2007","unstructured":"Suarez-Almazor ME, Kallen MA, Roundtree AK, et al. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007; 34(8): 1718\u20131726.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_11_2","article-title":"Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, symptom burden index (SBI), University of California, Los Angeles, scleroderma clinical trials consortium gastrointestinal scale (UCLA SCTC GIT) 2.0, baseline dyspnea index (BDI) and transition dyspnea index (TDI) (Mahler\u2019s Index), Cambridge pulmonary hypertension outcome review (CAMPHOR), and Raynaud\u2019s condition score (RCS)","author":"Pope J.","year":"2011","unstructured":"Pope J. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, symptom burden index (SBI), University of California, Los Angeles, scleroderma clinical trials consortium gastrointestinal scale (UCLA SCTC GIT) 2.0, baseline dyspnea index (BDI) and transition dyspnea index (TDI) (Mahler\u2019s Index), Cambridge pulmonary hypertension outcome review (CAMPHOR), and Raynaud\u2019s condition score (RCS). Arthritis Care Res 2011; 63 suppl 11: S98\u2013S111.","journal-title":"Arthritis Care Res"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319866615"},{"issue":"5","key":"e_1_3_3_13_2","first-page":"832","article-title":"Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial","volume":"32","author":"Khanna D","year":"2005","unstructured":"Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32(5): 832\u2013840.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02329-2"},{"issue":"6","key":"e_1_3_3_15_2","first-page":"1117","article-title":"Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases","volume":"33","author":"Johnson SR","year":"2006","unstructured":"Johnson SR, Glaman DD, Schentag CT, et al. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33(6): 1117\u20131122.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez300"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110225"},{"key":"e_1_3_3_18_2","first-page":"57","article-title":"Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis","volume":"31","author":"Bae S","year":"2013","unstructured":"Bae S, Allanore Y, Furst DE, et al. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol 2013; 31(2 suppl 76): 57\u201363.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq296"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"e_1_3_3_21_2","article-title":"Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis","volume":"32","author":"Kum\u00e1novics G","year":"2014","unstructured":"Kum\u00e1novics G, G\u00f6rbe E, Minier T, et al. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis. Clin Exp Rheumatol 2014; 32(6 suppl 86): S138\u2013S144.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11091606"},{"issue":"5","key":"e_1_3_3_23_2","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries JF","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9(5): 789\u2013793.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401110"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3800-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24730"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03063-1"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209768"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573397117666210913102759"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq022"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180004"},{"key":"e_1_3_3_33_2","article-title":"Reliability and validity of the Italian version of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument in patients with systemic sclerosis","volume":"33","author":"Gualtierotti R","year":"2015","unstructured":"Gualtierotti R, Ingegnoli F, Two R, et al. Reliability and validity of the Italian version of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument in patients with systemic sclerosis. Clin Exp Rheumatol 2015; 33(4 suppl 91): S55\u2013S60.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_34_2","article-title":"Development and validation of French version of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"29","author":"Bae S","year":"2011","unstructured":"Bae S, Allanore Y, Coustet B, et al. Development and validation of French version of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. Clin Exp Rheumatol 2011; 29(2 suppl 65): S15\u2013S21.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac118"},{"key":"e_1_3_3_36_2","unstructured":"van Leeuwen N Fretheim H Molberg \u00d8 et al. Severity and evolution over time of gastro-intestinal involvement in patients with systemic sclerosis in two large and independent cohorts ACR\/ARP Annual Meeting Abstracts number: 707 2019 https:\/\/acrabstracts.org\/abstract\/severity-and-evolution-over-time-of-gastro-intestinal-involvement-in-patients-with-systemic-sclerosis-in-two-large-and-independent-cohorts\/ (accessed 31 January 2025)."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171186"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-015-0176-2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103448"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00929-1"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0"},{"key":"e_1_3_3_42_2","first-page":"104","article-title":"Anaemia: a disease or symptom","volume":"78","author":"Newhall DA","year":"2020","unstructured":"Newhall DA, Oliver R, Lugthart S. Anaemia: a disease or symptom. Neth J Med 2020; 78: 104\u2013110.","journal-title":"Neth J Med"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3529-x"},{"key":"e_1_3_3_44_2","article-title":"A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"33","author":"Gorga M","year":"2015","unstructured":"Gorga M, Mihai C, Soare AM, et al. A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 2015; 33(4 suppl 91): S61\u2013S67.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"e_1_3_3_45_2","first-page":"1656","article-title":"Gastrointestinal disorders in systemic sclerosis: cluster analysis and prognosis from a French prospective cohort","volume":"42","author":"Molli\u00e8re C","year":"2024","unstructured":"Molli\u00e8re C, Gu\u00e9don AF, Kapel N, et al. Gastrointestinal disorders in systemic sclerosis: cluster analysis and prognosis from a French prospective cohort. Clin Exp Rheumatol 2024; 42(8): 1656\u20131664.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3680-y"},{"key":"e_1_3_3_47_2","article-title":"Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch","volume":"32","author":"Meijs J","year":"2014","unstructured":"Meijs J, Pors D, Vliet Vlieland TP, et al. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch. Clin Exp Rheumatol 2014; 32(6 suppl 86): S41\u2013S48.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2018.17856"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220702"}],"container-title":["Journal of Scleroderma and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23971983251345284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23971983251345284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23971983251345284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:53:08Z","timestamp":1777981988000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23971983251345284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/23971983251345284"],"URL":"https:\/\/doi.org\/10.1177\/23971983251345284","relation":{},"ISSN":["2397-1983","2397-1991"],"issn-type":[{"value":"2397-1983","type":"print"},{"value":"2397-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}